


Stabilis



Gentamicin sulfate



Noms commerciaux

| | |
|--------------|---|
| Amplomicina | Brésil |
| Azupel | Pérou |
| Cidomycin | Egypte, Grande Bretagne, Irlande |
| Dabroson | Grèce |
| Epigent | Egypte |
| Garalone | Portugal |
| Garamicina | Brésil |
| Garamycin | Afrique du sud, Croatie, Danemark, Egypte, Grèce, Norvège, Slovénie, Suède, Suisse, Turquie |
| Gencin | Allemagne |
| Genmisin | Turquie |
| Gensif | Turquie |
| Gensumycin | Finlande, Norvège, Suède |
| Genta | Turquie |
| Genta-Gobens | Espagne |
| Gentalline | France |
| Gentamen | Italie |
| Gentamival | Espagne |
| Gentaplast | Brésil |
| Genticin | Grande Bretagne |
| Gentomil | Italie |
| Gentreks | Turquie |
| Geomycine | Belgique |
| Getamisin | Turquie |
| Gevramycin | Espagne |
| Hexamycin | Danemark |
| Plurisemina | Argentine |
| Refobacin | Allemagne, Autriche |
| Regaminol | Egypte |
| Rupegen | Argentine |



Stabilité des solutions

| Container | Light | Concentration | Temperature | Stability | Shelf Life | Other | Reference |
|-----------|-------|---------------|-------------|-----------|------------|-------|-----------|
| | | | | | | | |
| | | 10 mg/ml | 4°C | | 84 | | 1486 |
| PVC | | 1 mg/ml | -20°C | | 30 | | 573 |
| PVC | | 1 mg/ml | 4°C | | 48 | | 434 |

| | | | | | | | | |
|-----|--|---------------|-----------|--|-----|--|--|------|
| PVC | | 1,2 mg/ml | -20°C | | 28 | | | 565 |
| PVC | | 1 mg/ml | 25°C | | 48 | | | 434 |
| PVC | | 1 mg/ml | 25°C | | 48 | | | 434 |
| PVC | | 1,6 mg/ml | -20°C | | 30 | | | 576 |
| PVC | | 0,02 mg/ml | 25°C | | 14 | | | 3888 |
| PVC | | 0,02 mg/ml | 37°C | | 14 | | | 3888 |
| PVC | | 0,02 mg/ml | 4°C | | 14 | | | 3888 |
| PE | | 2,5 mg/ml | 25°C | | 112 | | | 3141 |
| EVA | | 0,85 mg/ml | 23°C | | 7 | | | 1704 |
| EVA | | 0,85 mg/ml | 4°C | | 30 | | | 1704 |
| | | 30 mg/ml | 22°C-23°C | | 48 | | | 639 |
| PI | | 0,5 & 5 mg/ml | 4°C | | 10 | | | 604 |
| PI | | 0,5 & 5 mg/ml | 25°C | | 24 | | | 604 |
| PI | | 0,5 & 5 mg/ml | 25°C | | 24 | | | 604 |
| ? | | 2,5 mg/ml | 37°C | | 96 | | | 3952 |



Stabilité en mélange

| | | 1 mg/ml | 23°C | | Cefpirome sulfate : 50 mg/ml | 8 | | 280 |
|-----|----|-----------------|-----------|--|--|----|--|------|
| | | 0,75 mg/ml | 20°C-23°C | | Granisetron hydrochloride : 0,5 mg/ml | 4 | | 57 |
| | | 0,8 mg/ml | 25°C | | Cefazolin sodium : 10 mg/ml Clindamycin phosphate : 9 mg/ml | 12 | | 695 |
| | | 0,32 mg/ml | 23°C-25°C | | Dopamine hydrochloride : 0,8 mg/ml | 24 | | 738 |
| | | 0,8 mg/ml | 25°C | | Cefazolin sodium : 10 mg/ml Clindamycin phosphate : 9 mg/ml | 1 | | 695 |
| | | 3,2 mg/ml | 25°C | | Filgrastim : 40 µg/ml | 4 | | 104 |
| | | 5,26 mg/ml | 25°C | | Palonosetron hydrochloride : 26,7 µg/ml | 4 | | 2228 |
| | RL | 1 mg/ml | 23°C | | Cefpirome sulfate : 50 mg/ml | 8 | | 280 |
| | | 1 mg/ml | 23°C | | Cefpirome sulfate : 50 mg/ml | 8 | | 280 |
| | | 0,8 mg/ml | 25°C | | Ofloxacin : 2 mg/ml | 48 | | 889 |
| PVC | | 1,2 mg/ml | -20°C | | Clindamycin phosphate : 9 mg/ml | 28 | | 565 |
| PVC | | 1 mg/ml | 25°C | | Ciprofloxacin lactate : 1,5 mg/ml | 48 | | 434 |
| PVC | | 0,2 & 0,8 mg/ml | 25°C | | Aztreonam : 10 & 20 mg/ml | 8 | | 19 |

| | | | | | | | | |
|-----|--|-----------------|-----------|--|------------------------------------|-----|--|------|
| PVC | | 0,2 & 0,8 mg/ml | 4°C | | Aztreonam : 10 & 20 mg/ml | 24 | | 19 |
| PVC | | 1 mg/ml | 4°C | | Ciprofloxacin lactate : 1,5 mg/ml | 48 | | 434 |
| PVC | | 5 mg/ml | 25°C | | Clindamycin phosphate : 6 mg/ml | 24 | | 423 |
| PVC | | 0,02 mg/ml | 25°C | | Cefazolin sodium : 0,5 mg/ml | 4 | | 3888 |
| PVC | | 0,02 mg/ml | 25°C | | Vancomycin hydrochloride : 1 mg/ml | 14 | | 3888 |
| PVC | | 0,02 mg/ml | 37°C | | Vancomycin hydrochloride : 1 mg/ml | 4 | | 3888 |
| PVC | | 0,02 mg/ml | 37°C | | Cefazolin sodium : 0,5 mg/ml | 24 | | 3888 |
| PVC | | 0,02 mg/ml | 4°C | | Cefazolin sodium : 0,5 mg/ml | 14 | | 3888 |
| PE | | 2,5 mg/ml | 25°C | | Trisodium citrate : 40 mg/ml | 112 | | 3141 |
| PP | | 0,1 mg/ml | 4°C | | Heparin sodium : 5000 UI/ml | 28 | | 3956 |
| POF | | 0,75 mg/ml | 23°C | | Linezolid : 1,80 mg/ml | 5 | | 2353 |
| POF | | 0,75 mg/ml | 4°C | | Linezolid : 1,80 mg/ml | 7 | | 2353 |
| | | 30 mg/ml | 22°C-23°C | | Clindamycin phosphate : 90 mg/ml | 48 | | 639 |
| | | 2,5 mg/ml | 37°C | | Sodium citrate : 40 mg/ml | 96 | | 3952 |
| | | 1,5 mg/ml | 22°C-28°C | | Daptomycin : 19,2 mg/ml | 2 | | 1937 |



Facteur influençant la stabilité

| | | | | |
|--|--|--|--|------|
| | | | | 1322 |
| | | | | 1917 |
| | | | | 3520 |
| | | | | 3643 |



Compatibilités

| | | | | |
|--|--|--|------|------|
| | | | | |
| | Gentamicin sulfate : 1.6 mg/ml Aciclovir sodium : 5 mg/ml | | 336 | |
| | | Gentamicin sulfate : 30 mg/ml Aciclovir sodium : 5 mg/ml | | 2335 |
| | | Gentamicin sulfate : 5 mg/ml Allopurinol sodium : 3 mg/ml | | 307 |
| | Gentamicin sulfate : 1 mg/ml Alprostadil : 15 µg/ml | | 3201 | |
| | Gentamicin sulfate : 5 mg/ml Amifostine : 10 mg/ml | | 3 | |
| | Gentamicin sulfate : 0.8 mg/ml Amiodarone hydrochloride : 4 mg/ml | | 385 | |

| | | | | |
|--|--|---|------|------|
| | | Gentamicin sulfate Amoxicillin sodium | | 3643 |
| | | Gentamicin sulfate Amoxicillin sodium | | 3527 |
| | | Gentamicin sulfate Amoxicillin sodium | | 3520 |
| | | Gentamicin sulfate Amoxicillin sodium / clavulanic acid | | 3520 |
| | | Gentamicin sulfate Amoxicillin sodium / clavulanic acid | | 3643 |
| | | Gentamicin sulfate : 40 mg/ml Amoxicillin sodium / clavulanic acid : 100/10 mg/ml | | 3824 |
| | | Gentamicin sulfate Amoxicillin sodium / clavulanic acid | | 3545 |
| | | Gentamicin sulfate : 5 mg/ml Amphotericin B cholesteryl sulfate complex : 0,83 mg/ml | | 921 |
| | | Gentamicin sulfate Ampicillin sodium | | 3520 |
| | | Gentamicin sulfate Ampicillin sodium | | 3643 |
| | | Gentamicin sulfate Ampicillin sodium - sulbactam sodium | | 3643 |
| | | Gentamicin sulfate Ampicillin sodium - sulbactam sodium | | 3520 |
| | | Gentamicin sulfate : 5 mg/ml Amsacrine : 1 mg/ml | | 253 |
| | | Gentamicin sulfate : 5 mg/ml Anidulafungin : 0.5 mg/ml | | 1982 |
| | | Gentamicin sulfate : 0,8 mg/ml Atosiban : 0,75 mg/ml | | 4642 |
| | | Gentamicin sulfate : 2 mg/ml Atracurium besylate : 0.5 mg/ml | | 402 |
| | | Gentamicin sulfate : 21 mg/ml Azithromycine : 2 mg/ml | | 1800 |
| | | Gentamicin sulfate : 0.2 & 0.8 mg/ml Aztreonam : 10 & 20 mg/ml | | 19 |
| | | Gentamicin sulfate : 5 mg/ml Aztreonam : 40 mg/ml | | 99 |
| | | Gentamicin sulfate : 5 mg/ml Bivalirudin : 5 mg/ml | | 1713 |
| | | Gentamicin sulfate : 10 mg/ml Caffeine : 10 mg/ml | | 3964 |
| | | Gentamicin sulfate Calcium gluconate | | 3644 |
| | | Gentamicin sulfate : 5 mg/ml Caspofungin acetate : 0,7 mg/ml | | 2247 |
| | | Gentamicin sulfate Cefalotin sodium | | 3643 |
| | | Gentamicin sulfate Cefalotin sodium | | 3520 |
| | | Gentamicin sulfate Cefamandole nafate : 2 >> 100 mg/ml | | 612 |

| | | | | |
|--|--|---|--|------|
| | | Gentamicin sulfate Cefamandole nafate | | 3643 |
| | | Gentamicin sulfate Cefamandole nafate | | 3546 |
| | | Gentamicin sulfate Cefamandole nafate | | 3520 |
| | | Gentamicin sulfate Cefazolin sodium | | 3520 |
| | | Gentamicin sulfate Cefazolin sodium | | 3643 |
| | | Gentamicin sulfate Cefepime dihydrochloride | | 3643 |
| | | Gentamicin sulfate Cefepime dihydrochloride | | 3548 |
| | | Gentamicin sulfate : 6 mg/ml Cefepime dihydrochloride : 125 mg/ml | | 2141 |
| | | Gentamicin sulfate Cefepime dihydrochloride | | 3520 |
| | | Gentamicin sulfate : 5 mg/ml Cefiderocol sulfate tosylate : 20 mg/mL | | 4528 |
| | | Gentamicin sulfate Cefmenoxime | | 3643 |
| | | Gentamicin sulfate Cefmenoxime | | 3520 |
| | | Gentamicin sulfate Cefmetazole sodium | | 3520 |
| | | Gentamicin sulfate Cefmetazole sodium | | 3643 |
| | | Gentamicin sulfate Cefonicid sodium | | 3643 |
| | | Gentamicin sulfate Cefonicid sodium | | 3520 |
| | | Gentamicin sulfate Cefoperazone sodium | | 3544 |
| | | Gentamicin sulfate Cefoperazone sodium | | 3520 |
| | | Gentamicin sulfate Cefoperazone sodium | | 3643 |
| | | Gentamicin sulfate : 0.8 mg/ml Cefoperazone sodium : 10 mg/ml | | 1206 |
| | | Gentamicin sulfate Ceforanide | | 3520 |
| | | Gentamicin sulfate Ceforanide | | 3643 |
| | | Gentamicin sulfate Cefotaxime sodium | | 3520 |
| | | Gentamicin sulfate Cefotaxime sodium | | 3643 |
| | | Gentamicin sulfate Cefoxitin sodium | | 3520 |
| | | Gentamicin sulfate Cefoxitin sodium | | 3643 |

| | | | | |
|--|--|---|----|------|
| | | Gentamicin sulfate : 1 mg/ml Cefpirome sulfate : 50 mg/ml | RL | 280 |
| | | Gentamicin sulfate Cefpirome sulfate | | 3520 |
| | | Gentamicin sulfate Cefpirome sulfate | | 3643 |
| | | Gentamicin sulfate : 1 mg/ml Cefpirome sulfate : 50 mg/ml | | 280 |
| | | Gentamicin sulfate Cefpirome sulfate | | 3677 |
| | | Gentamicin sulfate : 1 mg/ml Cefpirome sulfate : 50 mg/ml | | 280 |
| | | Gentamicin sulfate : 5 mg/ml Ceftaroline fosamil : 2,22 mg/ml | | 3249 |
| | | Gentamicin sulfate Ceftaroline fosamil | | 3520 |
| | | Gentamicin sulfate : 5 mg/ml Ceftaroline fosamil : 2,22 mg/ml | RL | 3249 |
| | | Gentamicin sulfate Ceftaroline fosamil | | 3643 |
| | | Gentamicin sulfate Ceftazidime | | 3520 |
| | | Gentamicin sulfate Ceftazidime | | 3883 |
| | | Gentamicin sulfate Ceftazidime | | 3543 |
| | | Gentamicin sulfate : 6 mg/ml Ceftazidime : 125 mg/ml | | 2141 |
| | | Gentamicin sulfate Ceftazidime | | 3643 |
| | | Gentamicin sulfate : 6 mg/ml Ceftazidime : 83.3 mg/ml | | 1759 |
| | | Gentamicin sulfate Ceftazidime Avibactam | | 3643 |
| | | Gentamicin sulfate Ceftazidime Avibactam | | 3520 |
| | | Gentamicin sulfate Ceftizoxime sodium | | 3643 |
| | | Gentamicin sulfate Ceftizoxime sodium | | 3520 |
| | | Gentamicin sulfate Ceftobiprole medocaril sodium | | 4650 |
| | | Gentamicin sulfate Ceftobiprole medocaril sodium | | 3643 |
| | | Gentamicin sulfate : 5 mg/ml Ceftobiprole medocaril sodium : 2 mg/ml | | 2269 |
| | | Gentamicin sulfate Ceftobiprole medocaril sodium | | 3520 |
| | | Gentamicin sulfate : 5 mg/ml Ceftobiprole medocaril sodium : 2 mg/ml | RL | 2269 |
| | | Gentamicin sulfate Ceftolozane / tazobactam | | 3520 |

| | | | | |
|--|--|---|--|------|
| | | Gentamicin sulfate : 5 mg/ml Ceftolozane / tazobactam : 10/5 mg/ml | | 3828 |
| | | Gentamicin sulfate Ceftolozane / tazobactam | | 3643 |
| | | Gentamicin sulfate Ceftriaxone disodium | | 3643 |
| | | Gentamicin sulfate Ceftriaxone disodium | | 3523 |
| | | Gentamicin sulfate Ceftriaxone disodium | | 3520 |
| | | Gentamicin sulfate Cefuroxime sodium | | 3520 |
| | | Gentamicin sulfate Cefuroxime sodium | | 3643 |
| | | Gentamicin sulfate Cefuroxime sodium | | 3687 |
| | | Gentamicin sulfate Cefuzonam | | 3520 |
| | | Gentamicin sulfate Cefuzonam | | 3643 |
| | | Gentamicin sulfate : 0.08 mg/ml Cimetidine hydrochloride : 1.2 & 5 mg/ml | | 1201 |
| | | Gentamicin sulfate : 0.8 mg/ml Cimetidine hydrochloride : 3 mg/ml | | 1201 |
| | | Gentamicin sulfate : 1 mg/ml Ciprofloxacin lactate : 1.5 mg/ml | | 434 |
| | | Gentamicin sulfate : 10 mg/ml Ciprofloxacin lactate : 2 mg/ml | | 289 |
| | | Gentamicin sulfate : 1.6 mg/ml Ciprofloxacin lactate : 2 mg/ml | | 285 |
| | | Gentamicin sulfate : 1.6 mg/ml Ciprofloxacin lactate : 2 mg/ml | | 288 |
| | | Gentamicin sulfate : 5 mg/ml Cisatracurium besylate : 0.1 >> 5 mg/ml | | 299 |
| | | Gentamicin sulfate Cisplatin | | 3578 |
| | | Gentamicin sulfate Clindamycin phosphate | | 3526 |
| | | Gentamicin sulfate : 12 mg/ml Clindamycin phosphate : 90 mg/ml | | 639 |
| | | Gentamicin sulfate : 0.67 mg/ml Clindamycin phosphate : 6 mg/ml | | 423 |
| | | Gentamicin sulfate Cloxacillin sodium | | 3643 |
| | | Gentamicin sulfate : 40 mg/ml Cloxacillin sodium : 100 mg/ml | | 3012 |
| | | Gentamicin sulfate Cloxacillin sodium | | 3520 |
| | | Gentamicin sulfate : 15 mg/ml Cytarabine : 16 mg/ml | | 132 |
| | | Gentamicin sulfate Cytarabine | | 3580 |

| | | | | |
|--|--|--|--|------|
| | | Gentamicin sulfate Dalteparin sodium | | 3643 |
| | | Gentamicin sulfate : 1,5 mg/ml Daptomycin : 19,2 mg/ml | | 1937 |
| | | Gentamicin sulfate Daptomycin | | 2271 |
| | | Gentamicin sulfate Daunorubicin/cytarabine liposomale : 0,4 mg/mL | | 4654 |
| | | Gentamicin sulfate Daunorubicin/cytarabine liposomale | | 4354 |
| | | Gentamicin sulfate : 5 mg/ml Dexmedetomidine : 4 µg/ml | | 1712 |
| | | Gentamicin sulfate : 0.8 mg/ml Diatrizoate meglumine : 283 mg/ml | | 1085 |
| | | Gentamicin sulfate : 2.4 & 40 mg/ml Diltiazem hydrochloride : 5 mg/ml | | 198 |
| | | Gentamicin sulfate Dimenhydrinate | | 2087 |
| | | Gentamicin sulfate : 5 mg/ml Docetaxel : 0.9 mg/ml | | 1754 |
| | | Gentamicin sulfate Dopamine hydrochloride | | 3638 |
| | | Gentamicin sulfate : 2 mg/ml Dopamine hydrochloride : 0.8 mg/ml | | 738 |
| | | Gentamicin sulfate : 5 mg/ml Doripenem : 5 mg/ml | | 2262 |
| | | Gentamicin sulfate : 10 mg/ml Doxapram hydrochloride : 2 mg/ml | | 1802 |
| | | Gentamicin sulfate : 5 mg/ml Doxorubicin hydrochloride liposome peg : 0.4 mg/ml | | 251 |
| | | Gentamicin sulfate : 0.8 mg/ml Enalaprilate : 0.05 mg/ml | | 1315 |
| | | Gentamicin sulfate Enoxaparin sodium | | 3643 |
| | | Gentamicin sulfate : 5 mg/ml Eravacycline : 0,6 mg/ml | | 4434 |
| | | Gentamicin sulfate Erythromycin lactobionate | | 3643 |
| | | Gentamicin sulfate Erythromycin lactobionate | | 3520 |
| | | Gentamicin sulfate Erythromycin lactobionate | | 3674 |
| | | Gentamicin sulfate : 0,8 mg/ml Esmolol hydrochloride : 10 mg/ml | | 384 |
| | | Gentamicin sulfate : 5 mg/ml Etoposide phosphate : 5 mg/ml | | 1410 |
| | | Gentamicin sulfate : 5 mg/ml Famotidine : 2 mg/ml | | 215 |
| | | Gentamicin sulfate : 0,8 mg/ml Famotidine | | 397 |
| | | Gentamicin sulfate : 5 mg/ml Fenoldopam mesylate : 80 µg/ml | | 1803 |






















| | | | | |
|--|--|---|-----------|------|
| | | Gentamicin sulfate : 10 mg/ml Fentanyl citrate : 50 µg/ml | | 63 |
| | | Gentamicin sulfate : 1.6 mg/ml Filgrastim : 40 µg/ml | | 104 |
| | | Gentamicin sulfate : 5 mg/ml Filgrastim : 30 µg/ml | | 244 |
| | | Gentamicin sulfate Flucloxacillin sodium | | 3643 |
| | | Gentamicin sulfate Flucloxacillin sodium | | 3522 |
| | | Gentamicin sulfate : 2 mg/ml | | 4507 |
| | | Gentamicin sulfate | | 3643 |
| | | Gentamicin sulfate | | 3520 |
| | | Gentamicin sulfate : 5 mg/ml | | 301 |
| | | Gentamicin sulfate : 1 mg/ml | | 939 |
| | | Gentamicin sulfate : 10 & 40 mg/ml | | 999 |
| | | Gentamicin sulfate : 10 mg/ml | | 316 |
| | | Gentamicin sulfate : 0,05 mg/ml | | 4445 |
| | | Gentamicin sulfate : 1 mg/ml Fluconazole : 2 mg/ml | | 256 |
| | | Gentamicin sulfate : 4 mg/ml Fluconazole : 2 mg/ml | | 496 |
| | | Gentamicin sulfate : 5 mg/ml | | 1415 |
| | | Gentamicin sulfate : 5 mg/ml Fludarabine phosphate : 1 mg/ml | | 492 |
| | | Gentamicin sulfate : 2 mg/ml Foscarnet sodium : 24 mg/ml | | 1135 |
| | | Gentamicin sulfate : 4 mg/ml Foscarnet sodium : 24 mg/ml | | 73 |
| | | Gentamicin sulfate : 5 mg/ml Fosfomycin : 30 mg/ml | | 4055 |
| | | Gentamicin sulfate : 10 mg/ml Furosemide : 10 mg/ml | | 789 |
| | | Gentamicin sulfate : 6.4 mg/ml Furosemide : 5 mg/ml | | 805 |
| | | Gentamicin sulfate : 10 mg/ml | RL | 4603 |
| | | Gentamicin sulfate : 1,6 mg/ml Furosemide : 0,8 mg/ml | | 367 |
| | | Gentamicin sulfate : 8 mg/ml Furosemide : 1 mg/ml | | 1232 |
| | | Gentamicin sulfate : 5 mg/ml Gemcitabine hydrochloride : 10 mg/ml | | 1423 |
| | | Gentamicin sulfate : 1.5 mg/ml Granisetron hydrochloride : 1 mg/ml | | 57 |
| | | Gentamicin sulfate Heparin sodium | | 3643 |

| | | | | |
|--|--|--|--|------|
| | | Gentamicin sulfate : 40 mg/ml | | 673 |
| | | Gentamicin sulfate : 3 mg/ml Heparin sodium : 2500 UI/ml | | 4612 |
| | | Gentamicin sulfate : 4 >> 40 mg/ml Heparin sodium : 10 >> 40 UI/ml | | 1258 |
| | | Gentamicin sulfate Heparin sodium | | 3520 |
| | | Gentamicin sulfate Heparin sodium | | 1022 |
| | | Gentamicin sulfate : 1 & 2 mg/ml Heparin sodium : 2500 UI/ml | | 4612 |
| | | Gentamicin sulfate : 0,4 mg/ml | | 4440 |
| | | Gentamicin sulfate Heparin sodium | | 3540 |
| | | Gentamicin sulfate : 4 & 5 mg/ml Heparin sodium : 2500 UI/ml | | 4612 |
| | | Gentamicin sulfate : 2 mg/ml Heparin sodium : 50 UI/ml | | 317 |
| | | Gentamicin sulfate : 5 mg/ml Hetastarch : 60 mg/ml | | 1721 |
| | | Gentamicin sulfate : 0.8 mg/ml Hetastarch : 60 mg/ml | | 472 |
| | | Gentamicin sulfate : 0.8 mg/ml Hydromorphone hydrochloride : 0.2 mg/ml | | 405 |
| | | Gentamicin sulfate : 3 mg/ml Idarubicin hydrochloride : 1 mg/ml | | 491 |
| | | Gentamicin sulfate : 1 mg/ml Indomethacin sodium trihydrate : 0,5 & 1 mg/ml | | 494 |
| | | Gentamicin sulfate : 1 mg/ml Indomethacin sodium trihydrate : 0,5 & 1 mg/ml | | 1745 |
| | | Gentamicin sulfate : 1.2 >> 2 mg/ml Insulin : 0.2 UI/ml | | 129 |
| | | Gentamicin sulfate : 0.8 mg/ml Iohexol : 300 mg I/ml | | 1085 |
| | | Gentamicin sulfate : 0.8 mg/ml Ioxaglate : 320 mg I/ml | | 1085 |
| | | Gentamicin sulfate : 5 mg/ml Isavuconazonium sulfate : 1.5 mg/ml | | 3829 |
| | | Gentamicin sulfate : 40 mg/ml Ketamine hydrochloride : 50 mg/ml | | 2109 |
| | | Gentamicin sulfate : 0.8 mg/ml Labetalol hydrochloride : 1 mg/ml | | 386 |
| | | Gentamicin sulfate : 5 mg/ml Lansoprazole : 0.55 mg/ml | | 1625 |
| | | Gentamicin sulfate : 10 mg/ml Levofloxacin : 5 mg/ml | | 1072 |
| | | Gentamicin sulfate : 0,75 mg/ml Linezolid : 1,80 mg/ml | | 2353 |
| | | Gentamicin sulfate : 5 mg/ml Linezolid : 2 mg/ml | | 1925 |
| | | Gentamicin sulfate : 3 mg/ml Lorazepam : 0.33 mg/ml | | 186 |

| | | | |
|--|---|--|------|
| | Gentamicin sulfate : 0.8 mg/ml Magnesium sulfate : 16.67 >> 100 mg/ml | | 1047 |
| | Gentamicin sulfate : 5 mg/ml Melphalan : 0.1 mg/ml | | 169 |
| | Gentamicin sulfate : 30 mg/ml Meropenem : 10 mg/ml | | 2335 |
| | Gentamicin sulfate : 40 mg/ml Meropenem : 50 mg/ml | | 4319 |
| | Gentamicin sulfate : 4 mg/ml Meropenem : 1 & 50 mg/ml | | 266 |
| | Gentamicin sulfate : 0.8 mg/ml Meropenem : 1 & 20 mg/ml | | 266 |
| | Gentamicin sulfate Metronidazole | | 3594 |
| | Gentamicin sulfate : 0,8 & 1,2 mg/ml Metronidazole : 5 mg/ml | | 1243 |
| | Gentamicin sulfate : 0.8 mg/ml Metronidazole : 5 mg/ml | | 1035 |
| | Gentamicin sulfate : 3 mg/ml Midazolam hydrochloride : 5 mg/ml | | 186 |
| | Gentamicin sulfate : 0.8 mg/ml Midazolam hydrochloride : 0.05 >> 0.4 mg/ml | | 1888 |
| | Gentamicin sulfate : 10 mg/ml Midazolam hydrochloride : 1 mg/ml | | 176 |
| | Gentamicin sulfate Mitomycin | | 4471 |
| | Gentamicin sulfate Mitomycin | | 3128 |
| | Gentamicin sulfate : 0.8 mg/ml Morphine sulfate : 1 mg/ml | | 405 |
| | Gentamicin sulfate : 1.2 & 2 mg/ml Morphine sulfate : 1 mg/ml | | 406 |
| | Gentamicin sulfate Moxalactam | | 3643 |
| | Gentamicin sulfate Moxalactam | | 3520 |
| | Gentamicin sulfate : 40 mg/ml N-acetylcysteine : 200 mg/ml | | 3766 |
| | Gentamicin sulfate Nadroparin | | 3643 |
| | Gentamicin sulfate Nafcillin sodium | | 3643 |
| | Gentamicin sulfate Nafcillin sodium | | 3520 |
| | Gentamicin sulfate : 40 mg/ml Naloxone hydrochloride : 0.4 mg/ml | | 3408 |
| | Gentamicin sulfate : 4.17 mg/ml Nefopam : 0.16 mg/ml | | 4254 |
| | Gentamicin sulfate : 0.8 mg/ml Nicardipine hydrochloride : 0.1 mg/ml | | 1490 |
| | Gentamicin sulfate : 0,8 mg/ml Ofloxacin : 2 mg/ml | | 889 |

| | | | | |
|--|--|---|--|------|
| | | Gentamicin sulfate : 5 mg/ml Ondansetron hydrochloride : 1 mg/ml | | 334 |
| | | Gentamicin sulfate : 5 mg/ml Oritavancin : 0.8 >>2 mg/ml | | 3152 |
| | | Gentamicin sulfate Oxacillin sodium | | 3643 |
| | | Gentamicin sulfate Oxacillin sodium | | 3520 |
| | | Gentamicin sulfate : 5 mg/ml Paclitaxel : 1.2 mg/ml | | 248 |
| | | Gentamicin sulfate : 5 mg/ml Palonosetron hydrochloride : 50 µg/ml | | 2228 |
| | | Gentamicin sulfate : 2 mg/ml Pancuronium bromide : 0.05 mg/ml | | 402 |
| | | Gentamicin sulfate Pantoprazole sodium | | 2090 |
| | | Gentamicin sulfate : 40 mg/ml Paracetamol : 10 mg/ml | | 4742 |
| | | Gentamicin sulfate : 5 mg/ml Pemetrexed disodium : 20 mg/ml | | 1953 |
| | | Gentamicin sulfate Penicillin G potassium | | 3643 |
| | | Gentamicin sulfate Penicillin G potassium | | 3520 |
| | | Gentamicin sulfate Penicillin G sodium | | 3520 |
| | | Gentamicin sulfate Penicillin G sodium | | 3643 |
| | | Gentamicin sulfate : 10 mg/ml Pentoxifyllin : 5 mg/ml | | 4543 |
| | | Gentamicin sulfate : 0.8 mg/ml Pethidine hydrochloride : 10 mg/ml | | 405 |
| | | Gentamicin sulfate : 10 mg/ml Phenytoin sodium : 50 mg/ml | | 789 |
| | | Gentamicin sulfate : 20 mg/ml Phloroglucinol : 2,5 mg/ml | | 3791 |
| | | Gentamicin sulfate Piperacillin sodium | | 3643 |
| | | Gentamicin sulfate Piperacillin sodium | | 3520 |
| | | Gentamicin sulfate Piperacillin sodium / tazobactam | | 3520 |
| | | Gentamicin sulfate Piperacillin sodium / tazobactam | | 3586 |
| | | Gentamicin sulfate Piperacillin sodium / tazobactam | | 3643 |
| | | Gentamicin sulfate Posaconazole | | 4380 |
| | | Gentamicin sulfate : 30 mg/ml Potassium chloride : 20 mEq/l | | 2335 |
| | | Gentamicin sulfate : 40 mg/ml Propofol | | 4524 |

| | | | | |
|--|--|---|----|------|
| | | Gentamicin sulfate : 2 mg/ml Propofol | | 660 |
| | | Gentamicin sulfate : 5 mg/ml Propofol : 10 mg/ml | ∅ | 300 |
| | | Gentamicin sulfate : 5 mg/ml Remifentanyl hydrochloride : 25 & 250 µg/ml | ▲ | 59 |
| | | Gentamicin sulfate : 40 mg/ml Salbutamol sulfate : 1 mg/ml | ∅ | 3216 |
| | | Gentamicin sulfate : 5 mg/ml Sargramostim : 10 µg/ml | ▲ | 335 |
| | | Gentamicin sulfate : 2,4 mg/ml Sodium bicarbonate : 40 mg/ml | ∅ | 3122 |
| | | Gentamicin sulfate Sodium bicarbonate | | 3520 |
| | | Gentamicin sulfate Sodium bicarbonate | | 3643 |
| | | Gentamicin sulfate : 1 >> 5 mg/ml Sodium citrate : 40 mg/ml | ∅ | 2019 |
| | | Gentamicin sulfate : 2.5 mg/ml Sodium citrate : 40 mg/ml | 💧 | 3952 |
| | | Gentamicin sulfate : 40 mg/ml Sugammadex : 100 mg/ml | ∅ | 3372 |
| | | Gentamicin sulfate : 5 mg/ml Sulbactam/durlobactam : 15/15 mg/ml | ▲ | 4801 |
| | | Gentamicin sulfate : 4 mg/ml Tacrolimus : 1000 µg/ml | ▲ | 479 |
| | | Gentamicin sulfate : 5 mg/ml Tedizolid phosphate : 0.8 mg/ml | ▲ | 3827 |
| | | Gentamicin sulfate Teicoplanine | | 3656 |
| | | Gentamicin sulfate : 5 mg/ml Telavancin hydrochloride : 7.5 mg/ml | RL | 3254 |
| | | Gentamicin sulfate : 5 mg/ml Telavancin hydrochloride : 7.5 mg/ml | ▲♦ | 3254 |
| | | Gentamicin sulfate : 6 mg/ml Temocilline : 83.33 mg/ml | 💧 | 2231 |
| | | Gentamicin sulfate Temocilline | | 3643 |
| | | Gentamicin sulfate Temocilline | | 2296 |
| | | Gentamicin sulfate Temocilline | | 3520 |
| | | Gentamicin sulfate : 5 mg/ml Teniposide : 0.1 mg/ml | ♦ | 905 |
| | | Gentamicin sulfate : 2 mg/ml Theophylline : 4 mg/ml | ∅ | 317 |
| | | Gentamicin sulfate : 40 mg/ml Thiopental sodium : 25 mg/ml | ▲ | 3767 |
| | | Gentamicin sulfate : 5 mg/ml Thiotepa : 1 mg/ml | ♦ | 249 |
| | | Gentamicin sulfate Ticarillin / clavulanic acid | | 3643 |

| | | | | |
|---|---|---|--|------|
|  |  | Gentamicin sulfate Ticarcillin / clavulanic acid | | 3587 |
|  |  | Gentamicin sulfate Ticarcillin / clavulanic acid | | 3520 |
| |  | Gentamicin sulfate Tigecycline |  | 3332 |
| |  | Gentamicin sulfate : 6 mg/ml Vancomycin hydrochloride : 10 mg/ml |  | 3385 |
| |  | Gentamicin sulfate : 1.2 mg/ml Vasopressin : 0.2 UI/ml |  | 2017 |
| |  | Gentamicin sulfate : 2 mg/ml Vecuronium bromide : 0.1 mg/ml |  | 402 |
| |  | Gentamicin sulfate : 0.16 mg/ml Verapamil hydrochloride : 0.08 mg/ml |  | 1057 |
| |  | Gentamicin sulfate : 5 mg/ml Vinorelbine tartrate : 1 mg/ml |  | 84 |
|  |  | Gentamicin sulfate : 1.6 mg/ml Warfarin sodium : 2 mg/ml |  | 315 |
| |  | Gentamicin sulfate : 2 mg/ml Zidovudine : 4 mg/ml |  | 337 |



Voie d'administration



Bibliographie

| | Type | Source |
|----|-------|---|
| 3 | Revue | Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212. |
| 19 | Revue | Bell RG, Lipford LC, Massanari MJ, Riley CM. Stability of intravenous admixtures of aztreonam and cefoxitin, gentamicin, metronidazole, or tobramycin. Am J Hosp Pharm 1986 ; 43: 1444-1453. |
| 57 | Revue | Mayron D, Gennaro AR. Stability and compatibility of granisetron hydrochloride in IV solutions and oral liquids and during simulated Y-site injection with selected drugs. Am J Health-Syst Pharm 1996 ; 53: 294-304. |
| 59 | Revue | Trissel LA, Gilbert DL, Martinez JF, Kim MC. Compatibility of remifentanyl hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2192-2196. |
| 63 | Revue | Marquardt Ed, Lam SSY. Visual compatibility of fentanyl citrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 811-812. |
| 73 | Revue | Lor E, Takagi J. Visual compatibility of foscarnet with other injectable drugs. Am J Hosp Pharm 1990 ; 47: 157-159. |

| | | |
|-----|-------|--|
| 84 | Revue | Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499. |
| 99 | Revue | Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090. |
| 104 | Revue | Hall PD, Yui D, Lyons S, Bosso JA. Compatibility of filgrastim with selected antimicrobial drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 185-189. |
| 129 | Revue | Smythe M, Malouf E. Visual compatibility of insulin with secondary intravenous drugs in admixtures. Am J Hosp Pharm 1991 ; 48: 125-126. |
| 132 | Revue | Najari Z, Rusho WJ. Compatibility of commonly used bone marrow transplant drugs during Y-site delivery. Am J Health-Syst Pharm 1997 ; 54: 181-184. |
| 169 | Revue | Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363. |
| 176 | Revue | Mantong ML, Marquardt ED. Visual compatibility of midazolam hydrochloride with selected drugs during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 2567-2568. |
| 186 | Revue | Swart EL, Mooren RAG, Van Loenen AC. Compatibility of midazolam hydrochloride and lorazepam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2020-2022. |
| 198 | Revue | Gayed AA, Kheshary PR, Hinkle RL. Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 516-520. |
| 215 | Revue | Keyi X, Gagnon N, Bisson C, Desmarais M, LeBel M. Stability of famotidine in polyvinyl chloride minibags and polypropylene syringes and compatibility of famotidine with selected drugs. Ann Pharmacotherapy 1993 ; 27: 422-426. |
| 244 | Revue | Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913. |
| 248 | Revue | Trissel LA, Martinez JF. Turbidimetric assessment of the compatibility of taxol with 42 other drugs during simulated Y-site injection. Am J Hosp Pharm 1993 ; 50: 300-304. |
| 249 | Revue | Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045. |
| 251 | Revue | Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713. |
| 253 | Revue | Trissel LA, Chandler SW, Folstad JT. Visual compatibility of amsacrine with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1990 ; 47: 2525-2528. |
| 256 | Revue | Inagaki K, Takagi J, Lor E, Lee KJ, Nii L, Gill MA. Stability of fluconazole in commonly used intravenous antibiotic solutions. Am J Hosp Pharm 1993 ; 50: 1206-1208. |

| | | |
|-----|-------|--|
| 266 | Revue | Patel PR. Compatibility of meropenem with commonly used injectable drugs. Am J Health-Syst Pharm 1996 ; 53: 2853-2855. |
| 280 | Revue | Allen LV, Stiles ML, Prince SJ, Sylvestri MF. Stability of cefpirome sulfate in the presence of commonly used intensive care drugs during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 2427-2433. |
| 285 | Revue | Elmore RL, Contois ME, Kelly J, Noe A, Poirier A. Stability and compatibility of admixtures of intravenous ciprofloxacin and selected drugs. Clin Ther 1996 ; 18: 246-255. |
| 288 | Revue | Cervenka P, Dejong DJ, Butler BL, Monzingo MD. Visual compatibility of injectable ciprofloxacin lactate with selected injectable drugs during simulated Y-site administration. Hosp Pharm 1992 ; 27: 957-958,961-962. |
| 289 | Revue | Jim LK. Physical and chemical compatibility of intravenous ciprofloxacin with other drugs. Ann Pharmacotherapy 1993 ; 27: 704-707. |
| 299 | Revue | Trissel LA, Martinez JF, Gilbert DL. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1735-1741. |
| 300 | Revue | Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292. |
| 301 | Revue | Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300. |
| 307 | Revue | Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799. |
| 315 | Revue | Bahal SM, Lee TJ, McGinnes M, Dobler GL. Visual compatibility of warfarin sodium injection with selected medications and solutions. Am J Health-Syst Pharm 1997 ; 54: 2599-2600. |
| 316 | Revue | Veltri M, Lee CKK. Compatibility of neonatal parenteral nutrient solutions with selected intravenous drugs. Am J Health-Syst Pharm 1996 ; 53: 2611-2613. |
| 317 | Revue | Kershaw BP, Monnier HL, Mason JH. Visual compatibility of premixed theophylline or heparin with selected drugs for IV administration. Am J Hosp Pharm 1993 ; 50: 1360-1362. |
| 334 | Revue | Trissel LA, Tramonte SM, Grilley BJ. Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 988-992. |
| 335 | Revue | Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplastic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406. |
| 336 | Revue | Forman JK, Lachs JR, Souney PF. Visual compatibility of acyclovir sodium with commonly used intravenous drugs during simulated Y-site injection. Am J Hosp Pharm 1987 ; 44: 1408-1409. |
| 337 | Revue | Bashaw ED, Amantea MA, Minor JR, Galleli JF. Visual compatibility of zidovudine with other drugs during simulated Y-site administration. Am J Hosp Pharm 1988 ; 45: 2532-2533. |

| | | |
|-----|-------|---|
| 367 | Revue | Thompson DF, Allen LV, Desai SR, Rao PS. Compatibility of furosemide with aminoglycoside admixtures. Am J Hosp Pharm 1985 ; 42: 116-119. |
| 384 | Revue | Colucci RD, Cobuzzi LE, Halpern NA. Visual compatibility of esmolol hydrochloride and various injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 630-632. |
| 385 | Revue | Benedict MK, Roche VF, Banakar UV, Hilleman DE. Visual compatibility of amiodarone hydrochloride with various antimicrobial agents during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 1117-1118. |
| 386 | Revue | Colucci RD, Cobuzzi LE, Halpern NA. Visual compatibility of labetalol hydrochloride injection with various injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 1357-1358. |
| 397 | Revue | Fong PA, Ward J. Visual compatibility of intravenous famotidine with selected drugs. Am J Hosp Pharm 1989 ; 46: 125-126. |
| 402 | Revue | Savitsky ME. Visual compatibility of neuromuscular blocking agents with various injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1990 ; 47: 820-821. |
| 405 | Revue | Nieves-Cordero AL, Luciw HM, Souney PF. Compatibility of narcotic analgesic solutions with various antibiotics during simulated Y-site injection. Am J Hosp Pharm 1985 ; 42: 1108-1109. |
| 406 | Revue | Smythe MA, Patel MA, Gasloli RA. Visual compatibility of narcotic analgesics with selected intravenous admixtures. Am J Hosp Pharm 1990 ; 47: 819-820. |
| 423 | Revue | Mansur JM, Abramowitz PW, Lerner SA, Smith RB, Townsend RJ. Stability and cost analysis of clindamycin-gentamicin admixtures given every eight hours. Am J Hosp Pharm 1985 ; 42: 332-335. |
| 434 | Revue | Goodwin SD, Nix DE, Heyd A, Wilton JH. Compatibility of ciprofloxacin injection with selected drugs and solutions. Am J Hosp Pharm 1991 ; 48: 2166-2171. |
| 472 | Revue | Wohlford JG, Fowler MD. Visual compatibility of hetastarch with injectable critical-care drugs. Am J Hosp Pharm 1989 ; 46: 995-996. |
| 479 | Revue | Min DI, Brown T, HWang GC. Visual compatibility of tacrolimus with commonly used drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 2964-2966. |
| 491 | Revue | Turowski RC, Durthaler JM. Visual compatibility of idarubicin hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2181-2184. |
| 492 | Revue | Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189. |
| 494 | Revue | Thompson DF, Heflin NR. Incompatibility of injectable indomethacin with gentamicin sulfate or tobramycin sulfate. Am J Hosp Pharm 1992 ; 49: 836,838. |
| 496 | Revue | Lor E, Sheybani T, Takagi J. Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1991 ; 48: 744-746. |

| | | |
|-----|-------------|---|
| 565 | Revue | Marble DA, Bosso JA, Townsend RJ. Compatibility of clindamycin phosphate with amikacin sulfate at room temperature and with gentamicin sulfate and tobramycin sulfate under frozen conditions. Drug Intell Clin Pharm 1986 ; 20: 960-963. |
| 573 | Revue | Dinel BA, Ayotte DL, Behme RJ, Black BL, Whitby JL. Stability of antibiotic admixtures frozen in minibags. Drug Intell Clin Pharm 1977 ; 11: 542-548. |
| 576 | Revue | Holmes CJ, Ausman RK, Walter CW, Kundsinn RB. Activity of antibiotic admixtures subjected to different freeze-thaw treatments. Drug Intell Clin Pharm 1980 ; 14: 353-357. |
| 604 | Laboratoire | Stabilité des médicaments dans l'Intermate® SV50, 100, 200 Baxter 1998 |
| 612 | Revue | Frale RA, Klink PR, Engel GL, Mundell EE. Stability of cefamandole nafate injection with parenteral solutions and additives. Am J Hosp Pharm 1982 ; 39: 622-627. |
| 639 | Revue | Zbrozek AS, Marble DA, Bosso JA, Bair JN, Townsend RJ. Compatibility and stability of clindamycin phosphate - aminoglycoside combinations within polypropylene syringes. Drug Intell Clin Pharm 1987 ; 21: 806-810. |
| 660 | Revue | Michaels MR, Stauffer GL, Haas DP. Propofol compatibility with other intravenous drug products - Two new methods of evaluating IV emulsion compatibility. Ann Pharmacotherapy 1996 ; 30: 228-232. |
| 673 | Revue | Bullock L, Clark JH, Fitzgerald JF, Glick MR, Hancock BG, Baenziger JC, Black CD. The stability of amikacin, gentamicin, and tobramycin in total nutrient admixtures. JPEN 1989 ; 13: 505-509. |
| 695 | Revue | Zbrozek AS, Marble DA, Bosso JA. Compatibility and stability of cefazolin sodium, clindamycin phosphate, and gentamicin sulfate in two intravenous solutions. Drug Intell Clin Pharm 1988 ; 22: 873-875. |
| 738 | Revue | Gardella LA, Kesler H, Amann A, Carter JE. Intropin (dopamine hydrochloride) intravenous admixture compatibility. Part 3: Stability with miscellaneous additives. Am J Hosp Pharm 1978 ; 35: 581-584. |
| 789 | Revue | Garner SS, Wiest DB. Compatibility of drugs separated by a fluid barrier in a retrograde intravenous infusion system. Am J Hosp Pharm 1990 ; 47: 604-606. |
| 805 | Revue | Oskroba DM, Leissing NC, Trissel LA. An automated process for determining the physical compatibility of drugs. Hosp Pharm 1997 ; 32: 1013-1020. |
| 889 | Revue | Janknegt R, Stratermans T, Cilissen J, Lohman JJHM, Hooymans PM. Ofloxacin intravenous. Compatibility with other antibacterial agents. Pharm Weekbl [Sci] 1991 ; 13: 207-209. |
| 905 | Revue | Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017. |
| 921 | Revue | Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292. |

| | | |
|------|-------|--|
| 939 | Revue | Gilbar PJ, Groves CF. Visual compatibility of total parenteral nutrition solution (Synthamin 17 Premix*) with selected drugs during simulated Y-site injection. Aust J Hosp Pharm 1994 ; 24: 167-170. |
| 999 | Revue | Watson D. Piggyback compatibility of antibiotics with pediatric parenteral nutrition solution. JPEN 1985 ; 9: 220-224. |
| 1022 | Revue | Hutchinson SMW. Heparin and aminoglycosides instability. Drug Intell Clin Pharm 1986 ; 20: 886. |
| 1035 | Revue | Bisaillon S, Sarrazin R. Compatibility of several antibiotics or hydrocortisone when added to metronidazole solution for intravenous infusion. J Parenter Sci Technol 1983 ; 37: 129-132. |
| 1047 | Revue | Souney PF, Colucci RD, Mariani G, Campbell D. Compatibility of magnesium sulfate solutions with various antibiotics during simulated Y-site injection. Am J Hosp Pharm 1984 ; 41: 323-324. |
| 1057 | Revue | Cutie MR. Compatibility of verapamil hydrochloride injection with commonly used additives. Am J Hosp Pharm 1983 ; 40: 1205-1207. |
| 1072 | Revue | Saltsmann CL, Tom CM, Mitchell A, Fan JH, Gailey RA. Compatibility of levofloxacin with 34 medications during simulated Y-site administration. Am J Health-Syst Pharm 1999 ; 56: 1458-1459. |
| 1085 | Revue | Irving HD, Burbridge BE. Incompatibility of contrast agents with intravascular medications. Radiology 1989 ; 173: 91-92. |
| 1135 | Revue | Baltz JK, Kennedy P, Minor JR, Gallelli J. Visual compatibility of foscarnet with other injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1990 ; 47: 2075-2077. |
| 1201 | Revue | Yuhus EM, Lofton FT, Rosenberg HA, Mayron D, Baldinus JG. Cimetidine hydrochloride compatibility III: Room temperature stability in drug admixtures. Am J Hosp Pharm 1981 ; 38: 1919-1922. |
| 1206 | Revue | Frear RS. Cefoperazone-aminoglycoside incompatibility. Am J Hosp Pharm 1983 ; 40: 564. |
| 1232 | Revue | Beatson C, Taylor A. A physical compatibility study of furosemide & flucloxacillin injections. Br J Pharm Pract 1987 ; 9: 223-226, 236. |
| 1243 | Revue | Rovers JP, Meneilly G, Souny PF, Rekhi GS, Drum D. The use of stability-indicating assays to determine the in vitro compatibility and stability of metronidazole / gentamicin admixtures. Can J Hosp Pharm 1989 ; 42: 143-146. |
| 1258 | Revue | Tyler LS, Rehder TL, Davis RB. Effect of gentamicin on heparin activity. Am J Hosp Pharm 1981 ; 38: 537-540. |
| 1315 | Revue | Halpern NA, Colucci RD, Alicea M, Greenstein R. Visual compatibility of enalaprilat with commonly used critical care medications during simulated Y-site injection. Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 294-297. |
| 1322 | Revue | Ennis CE, Merritt RJ, Neff DN. In vitro study of inline filtration of medications commonly administered to pediatric cancer patients. JPEN 1983 ; 7: 156-158. |

| | | |
|------|-------|--|
| 1410 | Revue | Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145. |
| 1415 | Revue | Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74. |
| 1423 | Revue | Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hydrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518. |
| 1486 | Revue | Nahata MC, Hipple TF, Strausbaugh SD. Stability of gentamicin diluted in 0.9% sodium chloride injection in glass syringes. Hosp Pharm 1987 ; 22: 1131-1132. |
| 1490 | Revue | Halpern NA, Colucci RD, Alicea M, Greenstein R. The compatibility of nicardipine hydrochloride injection with various ICU medications during simulated Y-site injection. Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 250-254. |
| 1625 | Revue | Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321. |
| 1704 | Revue | Xu QA, Trissel LA, Saenz A. Stability of gentamicin sulfate and tobramycin sulfate in autodose infusion system bags. Int J Pharm Compound 2002 ; 6: 152-154. |
| 1712 | Revue | Trissel LA, Saenz CA. Compatibility screening of Precedex during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 230-233. |
| 1713 | Revue | Trissel LA, Saenz CA. Compatibility screening of bivalirudin during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 311-315. |
| 1721 | Revue | Trissel LA, Williams KY, Baker MB. Compatibility screening of Hextend during simulated Y-site administration with other drugs. Int J Pharm Compound 2001 ; 5: 69-72. |
| 1745 | Revue | Thompson DF, Heflin NR. Incompatibility of injectable indomethacin with gentamicin sulfate or tobramycin sulfate. Am J Health-Syst Pharm 1992 ; 49: 836-838. |
| 1754 | Revue | Trissel LA, Gilbert DL, Wolkin AC. Compatibility of docetaxel with selected drugs during simulated Y-site administration. Int J Pharm Compound 1999 ; 3: 241-244. |
| 1759 | Revue | Servais H, Tulkens PM. Stability and compatibility of ceftazidime administered by continuous infusion to intensive care patients. Antimicrob Agents Chemother 2001 ; 45: 2643-2647. |
| 1800 | Revue | Voytilla KL, Tyler LS, Rusho WJ. Visual compatibility of azithromycin with 24 commonly used drugs during simulated Y-site delivery. Am J Health-Syst Pharm 2002 ; 59: 853-855. |
| 1802 | Revue | Bell MS, Nolt DH. Visual compatibility of doxapram hydrochloride with drugs commonly administered via a Y-site in the intensive care nursery. Am J Health-Syst Pharm 2003 ; 60: 193-194. |
| 1803 | Revue | Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85. |
| 1888 | Revue | Janknegt R, Van den Berg TJ, De Jong M, Oldenhof HGJ, Steenhoek A. Compatibility study of midazolam. Ziekenhuisfarmacie 1986 ; 2: 45-48. |

| | | |
|------|-------|---|
| 1917 | Revue | Graham AE, Speicher E, Williamson B. Analysis of gentamicin sulfate and a study of its degradation in dextrose solution. J Pharm Biomed Anal 1997 ; 15: 537- 543. |
| 1925 | Revue | Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519. |
| 1937 | Revue | Lai JJ, Brodeur SK. Physical and chemical stability of daptomycin with nine medications. Ann Pharmacotherapy 2004 ; 38: 1612-1616. |
| 1953 | Revue | Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 2289-2293. |
| 1982 | Revue | Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 834-837. |
| 2017 | Revue | Barker B, Feddema S, Rusho WJ, Dengg R. Visual compatibility of vasopressin with other injectable drugs. Am J Health-Syst Pharm 2005 ; 62: 1969-1976. |
| 2019 | Revue | Wazny L, Walker S, Moist L. Visual compatibility of gentamicin sulfate and 4% sodium citrate solutions. Am J Health-Syst Pharm 2005 ; 62: 1548-1550. |
| 2087 | Revue | Ferreira E, Forest JM, Hildgen P. Compatibility of dimenhydrinate injectable by Y administration. Pharmactuel 2004 ; 37: 17-20. |
| 2090 | Revue | Pere H, Chasse V, Forest JM, Hildgen P. Compatibility of injectable pantoprazole in Y-site administration. Pharmactuel 2004 ; 37: 193-196. |
| 2109 | Revue | Pelletier E, Forest JM, Hildgen P. Compatibilité de la kétamine injectable lors de l'administration en dérivé avec d'autres médicaments usuels. Pharmactuel 2006 ; 39: 71-75. |
| 2141 | Revue | Barinian N, Chanteux H, Viaene E, Servais H, Tulkens PM. Stability and compatibility study of cefepime in comparaison with ceftazidime for potential administration by continuous infusion under conditions pertinent to ambulatory treatment of cystic fibrosis patients and to administration in intensive care units. J Antimicrob Chemother 2003 ; 51: 651-658. |
| 2228 | Revue | Kupiec T, Ben M, Trusley C, Trissel LA. Compatibility and stability of palonosetron hydrochloride with gentamicin, metronidazole, or vancomycin during simulated Y-site administration. Int J Pharm Compound 2008 ; 12,2: 170-173. |
| 2231 | Revue | de Jongh R, Hens R, Basma V, mouton JW, Tulkens PM, Carryn S. Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection. J Antimicrob Chemother 2008 ; 61, 2: 382-388. |
| 2247 | Revue | Chan P, Heatherly K, Kupiec T.C, Trissel L.A. Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2008 ; 12, 3: 276-278. |
| 2262 | Revue | Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administration Am J Health-Syst Pharm 2008 ; 65: 1261-1265. |
| 2269 | Revue | Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H. Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551. |

| | | |
|------|-------------|--|
| 2271 | Laboratoire | Daptomycine (Cubicin®) Résumé des caractéristiques du produits Novartis 2006 |
| 2296 | Laboratoire | Témocilline (Negaban®) - Résumé des caractéristiques du produit Eumedica 2017 |
| 2335 | Revue | Canann D, Tyler L.S, Barker B, Condie C. Visual compatibility of i.v. medications routinely used in bone marrow transplant recipients Am J Health-Syst Pharm 2009 ; 66, 8: 727-729 |
| 2353 | Revue | Xu Q.A, Trissel L.A, Zhang Y, Williams K.Y. Compatibility and stability of linezolid injection admixed with gentamicin sulfate and tobramycin sulfate. Int J Pharm Compound 2000 ; 4, 6: 476-479. |
| 3012 | Revue | Sullivan T, Forrest J.M, Leclair G. Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration Hosp Pharm 2015 ; 50, 3: 214-220. |
| 3122 | Revue | Dotson B, Lynn S, Savakis K, Churchwell MD. Physical compatibility of 4% sodium citrate with selected antimicrobial agents. Am J Health-Syst Pharm 2010 ; 67: 1195-1198. |
| 3128 | Laboratoire | Mitomycine (Amétycine®) - Résumé Caractéristiques du Produit Prostrakan 2013 |
| 3141 | Revue | Cote D, Lok CE, Battistella M, Vercaigne L. Stability of Trisodium Citrate and Gentamicin Solution for Catheter Locks after Storage in Plastic Syringes at Room Temperature. Can J Hosp Pharm 2010 ; 63, 4: 304-311. |
| 3152 | Revue | Kumar A, Mann HJ. Visual compatibility of oritavancin diphosphate with selected coadministered drugs during simulated Y-site administration. Am J Health-Syst Pharm 2010 ; 67: 1640-1644. |
| 3201 | Revue | Dice JE. Physical compatibility of alprostadil with commonly used IV solutions and medications in the neonatal intensive care unit. J Pediatr Pharmacol Ther 2006 ; 11:233?6. |
| 3216 | Revue | Legris ME, Valiquette ME, Lavoie A, Forest JM, Leclair G. Compatibilité physique par évaluation visuelle du salbutamol injectable lors de son administration en Y. Pharmactuel 2011 ; 44, 1 : 14-18 |
| 3249 | Revue | Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB. Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2011 ; 68: 2163-2169. |
| 3254 | Revue | Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L. Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration Am J Health-Syst Pharm 2011 ; 68: 2265-2270. |
| 3332 | Laboratoire | Tigecycline (Tigacyl®) - Summary of Product characteristics Pfizer 2012 |
| 3372 | Revue | Hanci V, Ali Kiraz H, Ömür D, Ekin S, Uyan B, Yurtlu B.S. Precipitation in Gallipoli: Sugammadex / Amiodarone & Sugammadex / Dobutamine & Sugammadex / Protamine. Rev Bras Anesthesiol 2013 ; 63, 1: 163-166. |
| 3385 | Revue | Raverdi V, Ampe E, Hecq JD, Tulkens PM. Stability and compatibility of vancomycin for administration by continuous infusion. J Antimicrob Chemother 2013 ; 68: 1179-1182. |
| 3408 | Revue | Tollec S, Touzin K, Pelletier E, Forest J.M. Evaluation visuelle de la compatibilité physique de la naloxone avec d'autres médicaments intraveineux usuels. Pharmactuel 2013 ; 46, 1 : 16-21. |
| 3520 | Laboratoire | Cidomycin - Summary of product Characteristics. Sanofi 2011 |

| | | |
|------|-------------|---|
| 3522 | Laboratoire | Flucloxacillin - Summary of Product Characteristics. Actavis 2013 |
| 3523 | Laboratoire | Ceftriaxone (Rocephin®) - Summary of Product Characteristics. Roche 2018 |
| 3526 | Laboratoire | Clindamycin (Dalacin®) - Summary of Product Characteristics Pharmacia 2010 |
| 3527 | Laboratoire | Amoxicillin (Amoxil®) – Summary of Product Characteristics Glaxo Smith Kline 2018 |
| 3540 | Laboratoire | Heparin sodium - Summary of Product Characteristics. Wockhardt 2010 |
| 3543 | Laboratoire | Ceftazidime – Summary of Product Characteristics Wockhardt 2013 |
| 3544 | Laboratoire | Cefoperazone (Cefobid®) - Summary of Product Characteristics Pfizer 2006 |
| 3545 | Laboratoire | Amoxicilline / acide clavulanique - Résumé des caractéristiques du produit Mylan SAS 2009 |
| 3546 | Laboratoire | Cefamandole Flavelab - Résumé des caractéristiques du produit Panpharma SA 2007 |
| 3548 | Laboratoire | Cefepime (Maxipime®) - Summary of Product characteristics. Bristol Myers Squibb 2007 |
| 3578 | Laboratoire | Cisplatine - Summary of Product Characteristics Accord Healthcare 2011 |
| 3580 | Laboratoire | Cytarabine Accord - Résumé des caractéristiques du produit Accord Healthcare France 2016 |
| 3586 | Laboratoire | Piperacilline tazobactam Actavis® - Résumé des caractéristiques du produit Actavis France 2010 |
| 3587 | Laboratoire | Ticarcilline/acide clavulanique (Timentin®) - Summary of Product Characteristics GlaxoSmithKline 2014 |
| 3594 | Laboratoire | Metronidazole (Flagyl®) - Summary of Product Characteristics Zentiva 2013 |
| 3638 | Laboratoire | Dopamin (Dopamine 40 mg/mL sterile concentrate®) - Summary of Product Characteristics Hospira 2010 |
| 3643 | Laboratoire | Gentamicin sulphate (Cidomycin®) - Summary of Product Characteristics Sanofi 2015 |
| 3644 | Laboratoire | Calcium gluconate® - Summary of Product Characteristics Hameln Pharmaceuticals 2010 |
| 3656 | Laboratoire | Teicoplanine (Targocid®) - Résumé des caractéristiques du produit Sanofi Aventis France 2014 |
| 3674 | Laboratoire | Erythromycin lactobionate - Summary of Product Characteristics PanPharma 2016 |
| 3677 | Laboratoire | Cefpirome (Cefrom®) - Résumé des caractéristiques du produit Sanofi Aventis France 2008 |
| 3687 | Laboratoire | Cefuroxime sodium - Summary of Product Characteristics Stravencon 2013 |
| 3766 | Revue | Forrest J.M, Hildgen P. Compatibilité de l'acétylcystéine injectable lors de son administration en Y avec d'autres médicaments usuels Pharmactuel 2014 ; 47, 3 : 161-165. |
| 3767 | Revue | Legris M.E, Lavoie A, Forrest J.M, Hildgen P. Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels. Pharmactuel 2014 ; 47, 3 : 167-172. |


| | | |
|------|-------------|---|
| 3791 | Poster | Sadou Yaye H, Burtet E, Hamel C, Aljhni R, Gard C, Tilleul P. Étude de la compatibilité physico-chimique du phloroglucinol injectable durant les mélanges au sein des tubulures en Y. Apifh Congress, Paris November 2014 2014 |
| 3824 | Revue | Boudi S, Roy H, Forest JM, Leclair G. Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y. Pharmactuel 2023 2023;56,3:91-98 |
| 3827 | Poster | Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015 |
| 3828 | Poster | Thabit A.K, Hamada Y, Nicolau D.P. Ceftazidime/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015 |
| 3829 | Poster | So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavanazonium sulfate during simulated Y-site administration. ASHP Midyear 2015 |
| 3883 | Laboratoire | Ceftazidime - Résumé des caractéristiques du produit Arrow 2016 |
| 3888 | Revue | Ranganathan D, Naicker S., Wallis S.C, Lipman J, . Ratanjee S.K, Roberts J.A Stability of Antibiotics for Intraperitoneal Administration in Extraneal 7.5% Icodextrin Peritoneal Dialysis Bags (STAB Study). Perit Dial Int 2016 ; 36:421-426. |
| 3952 | Revue | Battistella M., Vercaigne L.M, Cote D., Lok C.E. Antibiotic lock: In vitro stability of gentamicin and sodium citrate stored in dialysis catheters at 37°C. Hemodial Int 2010 ; 14, 3 : 322-326. |
| 3956 | Revue | Bastani B; Amin K; Herr A. Prolonged Stability of Stored Vancomycin, Gentamicin, and Heparin for Use in the Antibiotic-Lock Technique. ASAIO Journal 2005 ; 51,6:761-763. |
| 3964 | Revue | Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G. Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments. Pharmactuel 2017 ; 50,1 : 27-33. |
| 4055 | Revue | Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44 |
| 4254 | Revue | D'Huart E, Vigneron J, Demoré B. Physical Compatibility of Intravenous Drugs Commonly Used in Intensive Care Units: An Observational Study and Physical Compatibility Laboratory Tests on Anti-Infective Drugs Pharmaceutical Technology in Hospital Pharmacy 2019 ;4,1:29-40 |
| 4319 | Revue | Lessard J-J, Caron E, Schérier H, Forest J-M, Leclair G. Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs. Hosp Pharm 2020 ; 55, 5: 332-337. |
| 4354 | Poster | Sicard G, Donnette M, Martin N, Gensollen S, Pourroy B, Fanciullino R. Compatibilité visuelle du Vyxeos lors d'administration en Y avec une sélection de médicaments injectables. GERPAC Congress 2019 2019 |
| 4380 | Laboratoire | Posaconazole (Noxafil®) - Summary of Product Characteristics Merck Sharp & Dohme Limited 2019 |
| 4434 | Revue | Avery L.M, Chen, I.H, Reyes, S, Nicolau, D.P, Kuti J.L. Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration. Clin Ther 2019 ; 41, 10: 2162-2170. |

| | | |
|------|-------------|---|
| 4440 | Revue | Omotani S, Aoe M, Esaki S, Nagai K, Hatsuda Y, Mukai J, Teramachi H, Myotoku M. Compatibility of Intravenous Fat Emulsion with Antibiotics for Secondary Piggyback Infusion. Ann Nutr Metab 2018 ; 73: 227-233. |
| 4445 | Revue | Reed M.D, Perry E.B, Fennell S.J, Brissie E.O, Ball W.D. Antibiotic compatibility and stability in a parenteral nutrition solution. Chemotherapy 1979 ; 25: 336-345. |
| 4471 | Laboratoire | Amétycine 10 mg poudre pour solution injectable - Résumé des caractéristiques du produit - Oct 10, 2019 Kyowa Kirin Pharma 2019 |
| 4507 | Revue | Ross E, Salinas A, Petty K, Her C, Carpenter J. Compatibility of medications with intravenous lipid emulsions: Effects of simulated Y-site mixing. Am J Health-Syst Pharm 2020 ;77,23:1980-1985 |
| 4524 | Poster | Stucki C, Sautter A-M, Bonnabry P. Physical compatibility of the propofol emulsion with 33 drugs used in anaesthesiology. ESCP Symposium, Geneva, Switzerland 2009 |
| 4528 | Revue | Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61 |
| 4543 | Revue | Senarathna G, Strunk T, Petrovski M, Batty K. Physical compatibility of pentoxifylline and intravenous medications. Archives of Disease in Childhood 2018 ;104:292–295. |
| 4603 | Revue | Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G. Compatibility of Lactated Ringer's Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration. Hosp Pharm 2021 ; 56, 4: 228-234. |
| 4612 | Revue | Villaba-Moreno AM, Gil-Navarro MV, Cotrina-Luque J, Pérez-Moreno MA, Chamorro-de Vega E. Estabilidad de la solución de gentamicina y heparina para sellado de catéter. OFIL 2014 24;2:86-90 |
| 4642 | Poster | Larossa garcia M, Jimenez-Lozano I, Boix-Montanés A, Mallandrich Miret M, Clemente Bautista M, cabanas Poy M.J., Gorgas Torner Compatibilidad en Y de atosiban y farmacois habitualmente utilizados en obstetricia. SEFH Congress (Virtual) October 2021 2021 |
| 4650 | Laboratoire | Ceftobiprole (Zevtera 500 mg powder for concentrate for solution for infusion.) Summary of Product Characteristics, Advanz Pharma updated 4 aug 2021. Advanz Pharma 2021 |
| 4654 | Poster | Sicard G, Donnette M, Martin N, Gensollen S, Pourroy B, Fanciullino R. Compatibilité visuelle du Vyxeos® lors d'administration en Y avec une sélection de médicaments injectables. Communication personnelle 2021 |
| 4742 | Revue | Macoviciuc M, Nguyen C, Forest J-M, Leclair G. Compatibilité physique de l'acétaminophène injectable avec 102 autres médicaments lors d'une administration en Y. Pharmactuel 2022 ; 55, 4: 247-255. |
| 4801 | Revue | Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm 2024 ;51,1: |

Stabilis



Gentamicin sulfate



Stabilité des préparations

| | | 80 mg @=? | NaCl 0.9% >>10 ml | 2-8°C | | 42 | | | 2547 |
|--|--|--|----------------------------------|-------|--|----|--|--|------|
| | | 140 mg @=? | NaCl 0.9% >>10 ml | 2-8°C | | 42 | | | 2547 |
| | | 80 mg @=? | NaCl 0.9% >>10 ml | 26°C | | 7 | | | 2547 |
| | | 140 mg @=? | NaCl 0.9% >>10 ml | 26°C | | 7 | | | 2547 |
| | | gentamicine sulfate 40 mg/ml @=? (Lymphomed) | Genoptoc® eye-drops 3 mg/ml 2 ml | 4-8°C | | 90 | | | 2487 |



Facteur influençant la stabilité

| | | | | |
|--|------|--|--|------|
| | 25°C | | | 2547 |
|--|------|--|--|------|



































































Bibliographie

| | Type | Source |
|------|-------|---|
| 2487 | Revue | McBride HA, Martinez DR, Trang JM, Lander RD, Helms HA. Stability of gentamicin sulfate and tobramycin sulfate in extemporaneously prepared ophthalmic solutions at 8 degrees C Am J Hosp Pharm 1991 ; 48: 507-509. |
| 2547 | Revue | Ho PC, Soh H, Lim SM, Yow KL. Stability of extemporaneously prepared gentamicin ophthalmic solutions. Ann Pharmacotherapy 2001 ;35:1293-1294. |



Dictionnaire

| | |
|--|--|
|  Antibiotique |  Injectable |
|  Noms commerciaux |  Stabilité des solutions |
|  Contenant |  Molécule |
|  Concentration |  Température |
|  Conservation |  Durée de stabilité |
|  Biosimilaire |  Données conflictuelles |
|  Bibliographie |  Verre |
|  Chlorure de sodium 0,9% |  A l'abri de la lumière |
|  Jour |  Polyvinyl chlorure |
|  NaCl 0,9% ou glucose 5% |  Heure |
|  Lumière |  Glucose 5% |
|  Extraneal® (Baxter) |  Polyéthylène |
|  Eau pour préparation injectable |  Avec ou sans lumière |
|  Ethylène vinyl acétate |  Seringue polypropylène |
|  Elastomère en polyisoprène |  Non précisée |
|  Non précisé |  Stabilité en mélange |
|  Solvant |  Molécule |
| RL Ringer lactate |  Chlorure de sodium 0,45% |
| ∅ Aucun |  Polypropylène |
|  Polyolefine |  Facteur influençant la stabilité |
|  Filtration |  Provoque |
|  Diminution de la concentration |  Diminution de la stabilité |
|  NaHCO ₃ |  Dégradation |
|  Compatibilités |  Compatible |
|  Précipitation immédiate |  Incompatible |
|  Précipitation en 1 heure |  Incompatibilité non précisée |
|  Instabilité chimique |  Turbidité immédiate |
|  Incompatibilité subvisuelle |  Instabilité de l'émulsion à 4 heures |
|  Nutrition parentérale (mélange ternaire) |  Dégagement gazeux |
|  Nutrition parentérale (mélange binaire) |  Précipitation en 2 heures |

| | |
|---|--|
|  Solvant spécifique |  Changement de couleur |
|  Précipitation en 15 minutes |  NaCl 0,45% Glucose 5% |
|  Instabilité de l'émulsion immédiate |  Voie d'administration |
|  Intraveineuse |  Perfusion intraveineuse |
|  Intramusculaire |  Sous cutanée |
|  Intrathécale |  Intraventriculaire |
|  Sous conjonctivale |  Bibliographie |
|  Collyre |  Stabilité des préparations |
|  Origine |  Excipient |
|  Flacon injectable |  Flacon plastique |
|  Dictionnaire | |